phenylephrine HCl

Phase 3Small molecule

Bayer

phenylephrine HCl is one of 60 small molecule programs targeting Cataract. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CataractActive, not recruiting

Seasonal Allergic RhinitisActive, not recruiting

CataractPhase 3

Active, not recruiting

Seasonal Allergic RhinitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Pred Forte

Novartis

Phase 3

6 2

Clobetasol Propionate

Bayer

Phase 3

3 3

KPI-121

KKala Pharmaceuticals, Inc.

Phase 3

1 4

phenylephrine HCl

Bayer

Phase 3

1 5

XG-102

XXigen SA

Phase 3

2 6

Zolymbus

AbbVie

Preclinical

—7

Neurontin

VViatris Specialty LLC

Preclinical

3 8

Kenalog

BBassett Healthcare

Preclinical

1 9

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pediatric1 trial

Phenylephrine Pediatric Pharmacokinetic Study

Completed·JJohnson & Johnson Consumer and Personal Products Worldwide·Phase 1·NCT00762567·36 enrolled

Seasonal Allergic Rhinitis1 trial

Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)

Completed· Bayer logo

Bayer·Phase 2·NCT01330017·539 enrolled

Cataract1 trial

A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement

Completed·OOmeros Corporation·Phase 3·NCT02132312·78 enrolled

Acetaminophen1 trial

Safety of Phenylephrine Hydrochloride, Acetaminophen, Dimethindene Maleate Compared to Phenylephrine Hydrochloride Alone in Healthy Volunteers

Withdrawn· Novartis logo

Novartis·Phase 1/2·NCT01026961

Drug1 trial

Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study

Completed· Bayer logo

Bayer·Phase 3·NCT04534452·347 enrolled

1 more indication

Single Dose1 trial

Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)

Completed· Bayer logo

Bayer·Phase 1·NCT01354418·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for phenylephrine HCl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — phenylephrine HCl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for phenylephrine HCl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

phenylephrine HCl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pediatric1 trial

Seasonal Allergic Rhinitis1 trial

Cataract1 trial

Acetaminophen1 trial

Drug1 trial

Single Dose1 trial

References

Drug Info

Quick Facts

Related News